-
Listing
-
Trading
Where European Government Bonds meet the futureFixed Income derivativesLer maisTrade Mini Bond Futures on main European Government Bonds
-
Clearing
Step into Europe’s next phase of Repo ClearingRepo ClearingLer maisEuronext is expanding its repo clearing services to boost market access, liquidity provision and collateral optimisation across Europe.
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLer maisEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Ler maisThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLer maisThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
About Euronext
Euronext strategic planInnovate for Growth 2027Ler maisShaping capital markets for future generations
Abivax
26/06/2015
EnterNext welcomes Abivax on Euronext in Paris
Professor Hartmut Ehrlich, CEO of Abivax, rings the closing bell.
Abivax specializes in the research, development and commercialization of anti-viral drugs and therapeutic vaccines for the treatment of severe infectious diseases.
At the end of 2014, the Group has a portfolio of three products in clinical development: ABX203 (therapeutic vaccine against chronic hepatitis B), ABX464 (new drug against HIV) and ABX196 (adjuvant vaccine against hepatitis B).